{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:55:14Z","timestamp":1790805314990,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Oral Sci"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/ijos.2016.3","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T10:22:51Z","timestamp":1458901371000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["New strategies against drug resistance to herpes simplex virus"],"prefix":"10.1038","volume":"8","author":[{"given":"Yu-Chen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"issue":"12","key":"BFijos20163_CR1","first-page":"e46","volume":"1","author":"CR Howard","year":"2012","unstructured":"Howard CR, Fletcher NF . Emerging virus diseases: can we ever expect the unexpected? Emerg Microbes Infect 2012; 1 (12): e46.","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"BFijos20163_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","volume":"5","author":"C Gilbert","year":"2002","unstructured":"Gilbert C, Bestman-Smith J, Boivin G . Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5 (2): 88\u2013114.","journal-title":"Drug Resist Updat"},{"issue":"5","key":"BFijos20163_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/eri.09.34","volume":"7","author":"SS Wilson","year":"2009","unstructured":"Wilson SS, Fakioglu E, Herold BC . Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther 2009; 7 (5): 559\u2013568.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"13","key":"BFijos20163_CR4","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1128\/JVI.02396-10","volume":"85","author":"A Markus","year":"2011","unstructured":"Markus A, Grigoryan S, Sloutskin A et al. Varicella-zoster virus (VZV) infection of neurons derived from human embryonic stem cells: direct demonstration of axonal infection, transport of VZV, and productive neuronal infection. J Virol 2011; 85 (13): 6220\u20136233.","journal-title":"J Virol"},{"issue":"11","key":"BFijos20163_CR5","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1128\/JCM.01714-13","volume":"51","author":"S Burrel","year":"2013","unstructured":"Burrel S, Ait-Arkoub Z, Voujon D et al. Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism. J Clin Microbiol 2013; 51 (11): 3616\u20133623.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"BFijos20163_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/psc.2489","volume":"19","author":"S Galdiero","year":"2013","unstructured":"Galdiero S, Falanga A, Tarallo R et al. Peptide inhibitors against herpes simplex virus infections. J Pept Sci 2013; 19 (3): 148\u2013158.","journal-title":"J Pept Sci"},{"issue":"1","key":"BFijos20163_CR7","doi-asserted-by":"publisher","first-page":"e1003896","DOI":"10.1371\/journal.ppat.1003896","volume":"10","author":"M Jones","year":"2014","unstructured":"Jones M, Dry IR, Frampton D et al. RNA-seq analysis of host and viral gene expression highlights interaction between varicella zoster virus and keratinocyte differentiation. PLoS Pathog 2014; 10 (1): e1003896.","journal-title":"PLoS Pathog"},{"key":"BFijos20163_CR8","doi-asserted-by":"publisher","first-page":"593757","DOI":"10.1155\/2015\/593757","volume":"2015","author":"PA Suazo","year":"2015","unstructured":"Suazo PA, Iba\u00f1ez FJ, Retamal-D\u00edaz AR et al. Evasion of early antiviral responses by herpes simplex viruses. Mediators Inflamm 2015; 2015: 593757.","journal-title":"Mediators Inflamm"},{"key":"BFijos20163_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1743-422X-8-9","volume":"8","author":"M Matsuura","year":"2011","unstructured":"Matsuura M, Takemoto M, Yamanishi K et al. Human herpesvirus 6 major immediate early promoter has strong activity in T cells and is useful for heterologous gene expression. Virol J 2011; 8: 9.","journal-title":"Virol J"},{"issue":"4","key":"BFijos20163_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1128\/JCM.05834-11","volume":"50","author":"Y Higashimoto","year":"2012","unstructured":"Higashimoto Y, Ohta A, Nishiyama Y et al. Development of a human herpesvirus 6 species-specific immunoblotting assay. J Clin Microbiol 2012; 50 (4): 1245\u20131251.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"BFijos20163_CR11","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1128\/JCM.00067-13","volume":"51","author":"N Schnepf","year":"2013","unstructured":"Schnepf N, Scieux C, Resche-Riggon M et al. Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard. J Clin Microbiol 2013; 51 (7): 2096\u20132102.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"BFijos20163_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jcv.2014.07.001","volume":"61","author":"JA Hill","year":"2014","unstructured":"Hill JA, Boeckh MJ, Sedlak RH et al. Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation. J Clin Virol 2014; 61 (2): 289\u2013292.","journal-title":"J Clin Virol"},{"issue":"8","key":"BFijos20163_CR13","doi-asserted-by":"publisher","first-page":"e0137096","DOI":"10.1371\/journal.pone.0137096","volume":"10","author":"MC Aichelburg","year":"2015","unstructured":"Aichelburg MC, Weseslindtner L, Mandorfer M et al. Association of CMV-specific T cell-mediated immunity with CMV DNAemia and development of CMV disease in HIV-1-infected individuals. PLoS One 2015; 10 (8): e0137096.","journal-title":"PLoS One"},{"issue":"12","key":"BFijos20163_CR14","doi-asserted-by":"publisher","first-page":"e51306","DOI":"10.1371\/journal.pone.0051306","volume":"7","author":"JL Espinoza","year":"2012","unstructured":"Espinoza JL, Takami A, Trung LQ et al. Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells. PLoS One 2012; 7 (12): e51306.","journal-title":"PLoS One"},{"issue":"8","key":"BFijos20163_CR15","doi-asserted-by":"publisher","first-page":"e1004333","DOI":"10.1371\/journal.ppat.1004333","volume":"10","author":"O Antsiferova","year":"2014","unstructured":"Antsiferova O, M\u00fcller A, R\u00e4mer PC et al. Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog 2014; 10 (8): e1004333.","journal-title":"PLoS Pathog"},{"key":"BFijos20163_CR16","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.1038\/ncomms7240","volume":"6","author":"HB Wang","year":"2015","unstructured":"Wang HB, Zhang H, Zhang JP et al. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun 2015; 6: 6240.","journal-title":"Nat Commun"},{"issue":"14","key":"BFijos20163_CR17","doi-asserted-by":"publisher","first-page":"12603","DOI":"10.18632\/oncotarget.3687","volume":"6","author":"M Lee","year":"2015","unstructured":"Lee M, Son M, Ryu E et al. Quercetin-induced apoptosis prevents EBV infection. Oncotarget 2015; 6 (14): 12603\u201312624.","journal-title":"Oncotarget"},{"issue":"6","key":"BFijos20163_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bcp.2012.12.011","volume":"85","author":"E De Clercq","year":"2013","unstructured":"De Clercq E . Antivirals: past, present and future. Biochem Pharmacol 2013; 85 (6): 727\u2013744.","journal-title":"Biochem Pharmacol"},{"key":"BFijos20163_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pharmtox-010510-100228","volume":"51","author":"E De Clercq","year":"2011","unstructured":"De Clercq E . A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 2011; 51: 1\u201324.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"BFijos20163_CR20","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/JCM.44.4.1584-1586.2006","volume":"44","author":"T Czartoski","year":"2006","unstructured":"Czartoski T, Liu C, Koelle DM et al. Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J Clin Microbiol 2006; 44 (4): 1584\u20131586.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"BFijos20163_CR21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1128\/AAC.00426-06","volume":"51","author":"P Schnitzler","year":"2007","unstructured":"Schnitzler P, Koch C, Reichling J . Susceptibility of drug-resistant clinical herpes simplex virus type 1 strains to essential oils of ginger, thyme, hyssop, and sandalwood. Antimicrob Agents Chemother 2007; 51 (5): 1859\u20131862.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"BFijos20163_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1128\/AAC.00615-10","volume":"55","author":"J Piret","year":"2011","unstructured":"Piret J, Boivin G . Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55 (2): 459\u2013472.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"BFijos20163_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000368297","volume":"5","author":"K Toriyama","year":"2014","unstructured":"Toriyama K, Inoue T, Suzuki T et al. Necrotizing keratitis caused by acyclovir-resistant herpes simplex virus. Case Rep Ophthalmol 2014; 5 (3): 325\u2013328.","journal-title":"Case Rep Ophthalmol"},{"issue":"5654","key":"BFijos20163_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/272583a0","volume":"272","author":"HJ Schaeffer","year":"1978","unstructured":"Schaeffer HJ, Beauchamp L, de Miranda P et al. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978; 272 (5654): 583\u2013585.","journal-title":"Nature"},{"issue":"5","key":"BFijos20163_CR25","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1128\/AAC.01054-08","volume":"53","author":"X S\u00e1ez-Llorens","year":"2009","unstructured":"S\u00e1ez-Llorens X, Yogev R, Arguedas A et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009; 53 (5): 1912\u20131920.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"BFijos20163_CR26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1365-2125.2009.03479.x","volume":"68","author":"K Ogungbenro","year":"2009","unstructured":"Ogungbenro K, Matthews I, Looby M et al. Population pharmacokinetics and optimal design of paediatric studies for famciclovir. Br J Clin Pharmacol 2009; 68 (4): 546\u2013560.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"BFijos20163_CR27","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/jmv.22194","volume":"83","author":"A Cattamanchi","year":"2011","unstructured":"Cattamanchi A, Saracino M, Selke S et al. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. J Med Virol 2011; 83 (10): 1696\u20131703.","journal-title":"J Med Virol"},{"issue":"7","key":"BFijos20163_CR28","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1128\/AAC.06423-11","volume":"56","author":"A Janoly-Dumenil","year":"2012","unstructured":"Janoly-Dumenil A, Rouvet I, Bleyzac N et al. A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection. Antimicrob Agents Chemother 2012; 56 (7): 3732\u20133738.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"BFijos20163_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/lt.22471","volume":"18","author":"AN Bedel","year":"2012","unstructured":"Bedel AN, Hemmelgarn TS, Kohli R . Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl 2012; 18 (3): 347\u2013354.","journal-title":"Liver Transpl"},{"issue":"3","key":"BFijos20163_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/infdis\/jir766","volume":"205","author":"AL Drake","year":"2012","unstructured":"Drake AL, Roxby AC, Ongecha-Owuor F et al. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial. J Infect Dis 2012; 205 (3): 366\u2013375.","journal-title":"J Infect Dis"},{"issue":"12","key":"BFijos20163_CR31","first-page":"2904","volume":"7","author":"MG Gopal","year":"2013","unstructured":"Gopal MG, Shannoma, Kumar BCS et al. A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster. J Clin Diagn Res 2013; 7 (12): 2904\u20132907.","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"BFijos20163_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/QAI.0b013e3182928eea","volume":"63","author":"T Perti","year":"2013","unstructured":"Perti T, Saracino M, Baeten JM et al. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr 2013; 63 (2): 201\u2013208.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"BFijos20163_CR33","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/jps.23140","volume":"101","author":"MR Gokulgandhi","year":"2012","unstructured":"Gokulgandhi MR, Barot M, Bagui M et al. Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis. J Pharm Sci 2012; 101 (9): 3249\u20133263.","journal-title":"J Pharm Sci"},{"issue":"1","key":"BFijos20163_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/tid.12014","volume":"15","author":"JD Momper","year":"2013","unstructured":"Momper JD, Zhao Y, Shapiro R et al. Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. Transpl Infect Dis 2013; 15 (1): 34\u201341.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"BFijos20163_CR35","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1128\/AAC.01343-13","volume":"58","author":"MG Vossen","year":"2014","unstructured":"Vossen MG, Gattringer KB, J\u00e4ger W et al. Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. Antimicrob Agents Chemother 2014; 58 (4): 1952\u20131955.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"BFijos20163_CR36","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1128\/AAC.00334-11","volume":"55","author":"C Gilbert","year":"2011","unstructured":"Gilbert C, Azzi A, Goyette N et al. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. Antimicrob Agents Chemother 2011; 55 (9): 4019\u20134027.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"BFijos20163_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/AAC.00561-13","volume":"58","author":"LR Minces","year":"2014","unstructured":"Minces LR, Nguyen MH, Mitsani D et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother 2014; 58 (1): 128\u2013135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"BFijos20163_CR38","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","volume":"4","author":"E De Clercq","year":"2005","unstructured":"De Clercq E, Hol\u00fd A . Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4 (11): 928\u2013940.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"BFijos20163_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/med.20128","volume":"28","author":"E De Clercq","year":"2008","unstructured":"De Clercq E . The discovery of antiviral agents: ten different compounds, ten different stories. Med Res Rev 2008; 28 (6): 929\u2013953.","journal-title":"Med Res Rev"},{"issue":"2","key":"BFijos20163_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1001\/archdermatol.2009.363","volume":"146","author":"L Castelo-Soccio","year":"2010","unstructured":"Castelo-Soccio L, Bernardin R, Stern J et al. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol 2010; 146 (2): 124\u2013126.","journal-title":"Arch Dermatol"},{"issue":"11","key":"BFijos20163_CR41","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1128\/AAC.01072-12","volume":"56","author":"M Strand","year":"2012","unstructured":"Strand M, Islam K, Edlund K et al. 2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 2012; 56 (11): 5735\u20135743.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"BFijos20163_CR42","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1128\/JVI.06995-11","volume":"86","author":"D Pan","year":"2012","unstructured":"Pan D, Coen DM . Quantification and analysis of thymidine kinase expression from acyclovir-resistant G-string insertion and deletion mutants in herpes simplex virus-infected cells. J Virol 2012; 86 (8): 4518\u20134526.","journal-title":"J Virol"},{"key":"BFijos20163_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/OPTH.S39113","volume":"7","author":"LD Turner","year":"2013","unstructured":"Turner LD, Beckingsale P . Acyclovir-resistant herpetic keratitis in a solid-organ transplant recipient on systemic immunosuppression. Clin Ophthalmol 2013; 7: 229\u2013232.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"BFijos20163_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1128\/JCM.02247-12","volume":"51","author":"S Kakiuchi","year":"2013","unstructured":"Kakiuchi S, Nonoyama S, Wakamatsu H et al. Neonatal herpes encephalitis caused by a virologically confirmed acyclovir-resistant herpes simplex virus 1 strain. J Clin Microbiol 2013; 51 (1): 356\u2013359.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"BFijos20163_CR45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/infdis\/jit437","volume":"209","author":"D Pan","year":"2014","unstructured":"Pan D, Kaye SB, Hopkins M et al. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J Infect Dis 2014; 209 (3): 345\u2013349.","journal-title":"J Infect Dis"},{"key":"BFijos20163_CR46","first-page":"532","volume":"21","author":"MA Latief","year":"2015","unstructured":"Latief MA, Chikama T, Ko JA et al. Inactivation of acyclovir-sensitive and -resistant strains of herpes simplex virus type 1 in vitro by photodynamic antimicrobial chemotherapy. Mol Vis 2015; 21: 532\u2013537.","journal-title":"Mol Vis"},{"issue":"3","key":"BFijos20163_CR47","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1182\/blood.V99.3.1085","volume":"99","author":"AA Langston","year":"2002","unstructured":"Langston AA, Redei I, Caliendo AM et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 2002; 99 (3): 1085\u20131088.","journal-title":"Blood"},{"issue":"1","key":"BFijos20163_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1386-6532(02)00263-9","volume":"26","author":"F Morfin","year":"2003","unstructured":"Morfin F, Thouvenot D . Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26 (1): 29\u201337.","journal-title":"J Clin Virol"},{"issue":"10","key":"BFijos20163_CR49","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1128\/JCM.01263-10","volume":"48","author":"D Watson-Jones","year":"2010","unstructured":"Watson-Jones D, Wald A, Celum C et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol 2010; 48 (10): 3496\u20133503.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"BFijos20163_CR50","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1128\/JVI.06620-11","volume":"86","author":"G Andrei","year":"2012","unstructured":"Andrei G, Topalis D, Fiten P et al. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol 2012; 86 (5): 2641\u20132652.","journal-title":"J Virol"},{"issue":"2","key":"BFijos20163_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jpids\/pis009","volume":"1","author":"AH Karaba","year":"2012","unstructured":"Karaba AH, Cohen LK, Glaubach T et al. Longitudinal characterization of herpes simplex virus (HSV) isolates acquired from different sites in an immune-compromised child: a new HSV thymidine kinase mutation associated with resistance. J Pediatric Infect Dis Soc 2012; 1 (2): 116\u2013124.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"11","key":"BFijos20163_CR52","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1128\/AAC.00669-10","volume":"54","author":"S Burrel","year":"2010","unstructured":"Burrel S, Deback C, Agut H et al. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54 (11): 4833\u20134842.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"BFijos20163_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","volume":"16","author":"TH Bacon","year":"2003","unstructured":"Bacon TH, Levin MJ, Leary JJ et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16 (1): 114\u2013128.","journal-title":"Clin Microbiol Rev"},{"key":"BFijos20163_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2334-1-24","volume":"1","author":"RT Sarisky","year":"2001","unstructured":"Sarisky RT, Bartus HR, Dennis SA et al. Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice. BMC Infect Dis 2001; 1: 24.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"BFijos20163_CR55","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1128\/JVI.75.4.1761-1769.2001","volume":"75","author":"RT Sarisky","year":"2001","unstructured":"Sarisky RT, Quail MR, Clark PE et al. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001; 75 (4): 1761\u20131769.","journal-title":"J Virol"},{"issue":"6","key":"BFijos20163_CR56","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","volume":"46","author":"UA Betz","year":"2002","unstructured":"Betz UA, Fischer R, Kleymann G et al. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother 2002; 46 (6): 1766\u20131772.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"BFijos20163_CR57","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1128\/AAC.47.6.1798-1804.2003","volume":"47","author":"J Duan","year":"2003","unstructured":"Duan J, Liuzzi M, Paris W et al. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother 2003; 47 (6): 1798\u20131804.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"BFijos20163_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1089\/jop.2007.0084","volume":"24","author":"HE Kaufman","year":"2008","unstructured":"Kaufman HE, Varnell ED, Gebhardt BM et al. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. J Ocul Pharmacol Ther 2008; 24 (1): 34\u201342.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"BFijos20163_CR59","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1128\/AAC.00133-12","volume":"56","author":"K Katsumata","year":"2012","unstructured":"Katsumata K, Weinberg A, Chono K et al. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Antimicrob Agents Chemother 2012; 56 (7): 3587\u20133591.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"BFijos20163_CR60","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/1087057113482586","volume":"18","author":"WR Shadrick","year":"2013","unstructured":"Shadrick WR, Ndjomou J, Kolli R et al. Discovering new medicines targeting helicases: challenges and recent progress. J Biomol Screen 2013; 18 (7): 761\u2013781.","journal-title":"J Biomol Screen"},{"issue":"10","key":"BFijos20163_CR61","doi-asserted-by":"publisher","first-page":"e1003652","DOI":"10.1371\/journal.ppat.1003652","volume":"9","author":"KN Mohni","year":"2013","unstructured":"Mohni KN, Smith S, Dee AR et al. Herpes simplex virus type 1 single strand DNA binding protein and helicase\/primase complex disable cellular ATR signaling. PLoS Pathog 2013; 9 (10): e1003652.","journal-title":"PLoS Pathog"},{"issue":"3","key":"BFijos20163_CR62","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1128\/AAC.01803-12","volume":"57","author":"K Katsumata","year":"2013","unstructured":"Katsumata K, Chono K, Kato K et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother 2013; 57 (3): 1339\u20131346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"BFijos20163_CR63","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1517\/14728222.2013.827663","volume":"17","author":"SK Weller","year":"2013","unstructured":"Weller SK, Kuchta RD . The DNA helicase-primase complex as a target for herpes viral infection. Expert Opin Ther Targets 2013; 17 (10): 1119\u20131132.","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"BFijos20163_CR64","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1128\/AAC.02641-14","volume":"58","author":"S Biswas","year":"2014","unstructured":"Biswas S, Sukla S, Goldner T et al. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model. Antimicrob Agents Chemother 2014; 58 (7): 3843\u20133852.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"BFijos20163_CR65","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm0402-392","volume":"8","author":"G Kleymann","year":"2002","unstructured":"Kleymann G, Fischer R, Betz UA et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002; 8 (4): 392\u2013398.","journal-title":"Nat Med"},{"issue":"1","key":"BFijos20163_CR66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/095632020701800104","volume":"18","author":"J Baumeister","year":"2007","unstructured":"Baumeister J, Fischer R, Eckenberg P et al. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother 2007; 18 (1): 35\u201348.","journal-title":"Antivir Chem Chemother"},{"issue":"1","key":"BFijos20163_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2006.11.006","volume":"75","author":"S Biswas","year":"2007","unstructured":"Biswas S, Jennens L, Field HJ . The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB\/c mice infected with herpes simplex virus type 1. Antiviral Res 2007; 75 (1): 30\u201335.","journal-title":"Antiviral Res"},{"issue":"7","key":"BFijos20163_CR68","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jis019","volume":"205","author":"S Tyring","year":"2012","unstructured":"Tyring S, Wald A, Zadeikis N et al. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis 2012; 205 (7): 1100\u20131110.","journal-title":"J Infect Dis"},{"key":"BFijos20163_CR69","unstructured":"Astellas A . Phase 1, randomized, double-blind, multiple dose, multi-center study to compare the safety of ASP2151 to valacylcovir and placebo in healthy male and female subjects. Available at \n                    http:\/\/ichgcp.net\/clinical-trials-registry\/NCT00870441\n                    \n                   accessed 21 January 2013."},{"issue":"1\/2","key":"BFijos20163_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejps.2011.07.005","volume":"44","author":"TS Vo","year":"2011","unstructured":"Vo TS, Ngo DH, Ta QV et al. Marine organisms as a therapeutic source against herpes simplex virus infection. Eur J Pharm Sci 2011; 44 (1\/2): 11\u201320.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"BFijos20163_CR71","first-page":"435","volume":"12","author":"R Namazi","year":"2013","unstructured":"Namazi R, Zabihollahi R, Behbahani M et al. Inhibitory activity of avicennia marina, a medicinal plant in persian folk medicine, against HIV and HSV. Iran J Pharm Res 2013; 12 (2): 435\u2013443.","journal-title":"Iran J Pharm Res"},{"issue":"2","key":"BFijos20163_CR72","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1039\/C2RA21464D","volume":"3","author":"MG Zhong","year":"2013","unstructured":"Zhong MG, Xiang YF, Qiu XX et al. Natural products as a source of anti-herpes simplex virus agents. RSC Adv 2013; 3 (2): 313\u2013328.","journal-title":"RSC Adv"},{"issue":"1","key":"BFijos20163_CR73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1574891X11308010011","volume":"8","author":"AD Vadlapudi","year":"2013","unstructured":"Vadlapudi AD, Vadlapatla RK, Mitra AK . Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective. Recent Pat Antiinfect Drug Discov 2013; 8 (1): 55\u201367.","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"6","key":"BFijos20163_CR74","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/10286020.2011.571645","volume":"13","author":"Y Pei","year":"2011","unstructured":"Pei Y, Du Q, Liao PY et al. Notoginsenoside ST-4 inhibits virus penetration of herpes simplex virus in vitro. J Asian Nat Prod Res 2011; 13 (6): 498\u2013504.","journal-title":"J Asian Nat Prod Res"},{"issue":"8","key":"BFijos20163_CR75","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.micinf.2004.03.009","volume":"6","author":"HY Cheng","year":"2004","unstructured":"Cheng HY, Lin TC, Yang CM et al. Mechanism of action of the suppression of herpes simplex virus type 2 replication by pterocarnin A. Microbes Infect 2004; 6 (8): 738\u2013744.","journal-title":"Microbes Infect"},{"issue":"4","key":"BFijos20163_CR76","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/jac\/dkh136","volume":"53","author":"HY Cheng","year":"2004","unstructured":"Cheng HY, Lin TC, Yang CM et al. Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. J Antimicrob Chemother 2004; 53 (4): 577\u2013583.","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"BFijos20163_CR77","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1021\/ja00222a067","volume":"110","author":"NB Perry","year":"1988","unstructured":"Perry NB, Blunt JW, Munro MHG et al. Mycalamide A, an antiviral compound from a New Zealand sponge of the genus Mycale. J Am ChemSoc 1988; 110 (14): 4850\u20134851.","journal-title":"J Am ChemSoc"},{"issue":"1","key":"BFijos20163_CR78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1021\/jo00288a037","volume":"55","author":"NB Perry","year":"1990","unstructured":"Perry NB, Blunt JW, Munro MHG et al. Antiviral and antitumor agents from a New Zealand sponge, Mycale sp. 2. Structures and solution conformations of mycalamides A and B. J Org Chem 1990; 55 (1): 223\u2013227.","journal-title":"J Org Chem"},{"issue":"12","key":"BFijos20163_CR79","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/82191","volume":"6","author":"S Crotty","year":"2000","unstructured":"Crotty S, Maag D, Arnold JJ et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6 (12): 1375\u20131379.","journal-title":"Nat Med"},{"issue":"12","key":"BFijos20163_CR80","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1073\/pnas.111085598","volume":"98","author":"S Crotty","year":"2001","unstructured":"Crotty S, Cameron CE, Andino R . RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98 (12): 6895\u20136900.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"BFijos20163_CR81","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1534\/genetics.109.106492","volume":"183","author":"P Chen","year":"2009","unstructured":"Chen P, Shakhnovich EI . Lethal mutagenesis in viruses and bacteria. Genetics 2009; 183 (2): 639\u2013650.","journal-title":"Genetics"},{"issue":"1548","key":"BFijos20163_CR82","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1098\/rstb.2010.0058","volume":"365","author":"G Martin","year":"2010","unstructured":"Martin G, Gandon S . Lethal mutagenesis and evolutionary epidemiology. Philos Trans R Soc Lond B Biol Sci 2010; 365 (1548): 1953\u20131963.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"5","key":"BFijos20163_CR83","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.semcancer.2010.10.005","volume":"20","author":"EJ Fox","year":"2010","unstructured":"Fox EJ, Loeb LA . Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin Cancer Biol 2010; 20 (5): 353\u2013359.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"BFijos20163_CR84","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3390\/v4112786","volume":"4","author":"H Moreno","year":"2012","unstructured":"Moreno H, Grande-P\u00e9rez A, Domingo E et al. Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses 2012; 4 (11): 2786\u20132805.","journal-title":"Viruses"},{"issue":"2","key":"BFijos20163_CR85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tim.2012.10.006","volume":"21","author":"MJ Dapp","year":"2013","unstructured":"Dapp MJ, Patterson SE, Mansky LM . Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol 2013; 21 (2): 56\u201362.","journal-title":"Trends Microbiol"},{"issue":"2","key":"BFijos20163_CR86","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1534\/genetics.113.154195","volume":"195","author":"JJ Bull","year":"2013","unstructured":"Bull JJ, Joyce P, Gladstone E et al. Empirical complexities in the genetic foundations of lethal mutagenesis. Genetics 2013; 195 (2): 541\u2013552.","journal-title":"Genetics"},{"issue":"8","key":"BFijos20163_CR87","doi-asserted-by":"publisher","first-page":"e71039","DOI":"10.1371\/journal.pone.0071039","volume":"8","author":"AM Ortega-Prieto","year":"2013","unstructured":"Ortega-Prieto AM, Sheldon J, Grande-P\u00e9rez A et al. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One 2013; 8 (8): e71039.","journal-title":"PLoS One"},{"issue":"23","key":"BFijos20163_CR88","doi-asserted-by":"publisher","first-page":"9403","DOI":"10.1021\/jm400653j","volume":"56","author":"LF Bonnac","year":"2013","unstructured":"Bonnac LF, Mansky LM, Patterson SE . Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis. J Med Chem 2013; 56 (23): 9403\u20139414.","journal-title":"J Med Chem"},{"issue":"7","key":"BFijos20163_CR89","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1128\/JVI.03483-14","volume":"89","author":"MD Pauly","year":"2015","unstructured":"Pauly MD, Lauring AS . Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 2015; 89 (7): 3584\u20133597.","journal-title":"J Virol"},{"issue":"2","key":"BFijos20163_CR90","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","volume":"80","author":"S Crotty","year":"2002","unstructured":"Crotty S, Cameron C, Andino R . Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002; 80 (2): 86\u201395.","journal-title":"J Mol Med"},{"issue":"6","key":"BFijos20163_CR91","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/17460794.3.6.553","volume":"3","author":"JD Graci","year":"2008","unstructured":"Graci JD, Cameron CE . Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol 2008; 3 (6): 553\u2013566.","journal-title":"Future Virol"},{"issue":"7","key":"BFijos20163_CR92","doi-asserted-by":"publisher","first-page":"e1001005","DOI":"10.1371\/journal.ppat.1001005","volume":"6","author":"AS Lauring","year":"2010","unstructured":"Lauring AS, Andino R . Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 2010; 6 (7): e1001005.","journal-title":"PLoS Pathog"},{"issue":"2","key":"BFijos20163_CR93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1128\/MMBR.05023-11","volume":"76","author":"E Domingo","year":"2012","unstructured":"Domingo E, Sheldon J, Perales C . Viral quasispecies evolution. Microbiol Mol Biol Rev 2012; 76 (2): 159\u2013216.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"11","key":"BFijos20163_CR94","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1128\/JVI.00201-09","volume":"83","author":"JM Cuevas","year":"2009","unstructured":"Cuevas JM, Gonz\u00e1lez-Candelas F, Moya A et al. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 2009; 83 (11): 5760\u20135764.","journal-title":"J Virol"},{"issue":"4050","key":"BFijos20163_CR95","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.177.4050.705","volume":"177","author":"RW Sidwell","year":"1972","unstructured":"Sidwell RW, Huffman JH, Khare GP et al. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177 (4050): 705\u2013706.","journal-title":"Science"},{"issue":"22","key":"BFijos20163_CR96","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1016\/j.bmc.2013.08.023","volume":"21","author":"JM Rawson","year":"2013","unstructured":"Rawson JM, Heineman RH, Beach LB et al. 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem 2013; 21 (22): 7222\u20137228.","journal-title":"Bioorg Med Chem"},{"issue":"32","key":"BFijos20163_CR97","doi-asserted-by":"publisher","first-page":"E3252","DOI":"10.1073\/pnas.1405635111","volume":"111","author":"D Li","year":"2014","unstructured":"Li D, Fedeles BI, Singh V et al. Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidine. Proc Natl Acad Sci USA 2014; 111 (32): E3252\u2013E3259.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"BFijos20163_CR98","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1073\/pnas.1415974112","volume":"112","author":"CS Peng","year":"2015","unstructured":"Peng CS, Fedeles BI, Singh V et al. Two-dimensional IR spectroscopy of the anti-HIV agent KP1212 reveals protonated and neutral tautomers that influence pH-dependent mutagenicity. Proc Natl Acad Sci USA 2015; 112 (11): 3229\u20133234.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"BFijos20163_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2005.03.004","volume":"67","author":"KS Harris","year":"2005","unstructured":"Harris KS, Brabant W, Styrchak S et al. KP-1212\/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 2005; 67 (1): 1\u20139.","journal-title":"Antiviral Res"},{"key":"BFijos20163_CR100","unstructured":"Anon. Nove anti-HIV agent enters Phase IIa clinical trial. Expert Rev Anti Infect Ther 2007; 5 (4): 540\u2013541."},{"issue":"5","key":"BFijos20163_CR101","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1039\/c0ob00495b","volume":"9","author":"HZ Yang","year":"2011","unstructured":"Yang HZ, Pan MY, Jiang DW et al. Synthesis of Janus type nucleoside analogues and their preliminary bioactivity. Org Biomol Chem 2011; 9 (5): 1516\u20131522.","journal-title":"Org Biomol Chem"},{"issue":"7","key":"BFijos20163_CR102","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1246\/cl.2011.684","volume":"40","author":"H Zhao","year":"2011","unstructured":"Zhao H, Huang W, Wu X et al. Synthesis of a complete Janus-type guanosine-cytosine base and its 2'-deoxyribonucleoside. Chem Lett 2011; 40 (7): 684\u2013686.","journal-title":"Chem Lett"},{"issue":"16","key":"BFijos20163_CR103","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1039\/c1ob05577a","volume":"9","author":"MY Pan","year":"2011","unstructured":"Pan MY, Hang W, Zhao XJ et al. Janus-type AT nucleosides: synthesis, solid and solution state structures. Org Biomol Chem 2011; 9 (16): 5692\u20135702.","journal-title":"Org Biomol Chem"},{"issue":"49","key":"BFijos20163_CR104","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1039\/c2cc31036h","volume":"48","author":"H Zhao","year":"2012","unstructured":"Zhao H, Huang W, Wu X et al. Different superstructures formed by Janus-type nucleosides. Chem Commun (Camb) 2012; 48 (49): 6097\u20136099.","journal-title":"Chem Commun (Camb)"},{"issue":"36","key":"BFijos20163_CR105","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1039\/c3cc41383g","volume":"49","author":"H Zhao","year":"2013","unstructured":"Zhao H, He S, Yang M et al. Micro-flowers changing to nano-bundle aggregates by translocation of the sugar moiety in Janus TA nucleosides. Chem Commun (Camb) 2013; 49 (36): 3742\u20133744.","journal-title":"Chem Commun (Camb)"},{"key":"BFijos20163_CR106","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1038\/ncomms4108","volume":"5","author":"H Zhao","year":"2014","unstructured":"Zhao H, Guo X, He S et al. Complex self-assembly of pyrimido[4,5-d]pyrimidine nucleoside supramolecular structures. Nat Commun 2014; 5: 3108.","journal-title":"Nat Commun"},{"issue":"47","key":"BFijos20163_CR107","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.1002\/chem.201403998","volume":"20","author":"S He","year":"2014","unstructured":"He S, Zhao H, Guo X et al. The readout of base-pair information in adenine-thymine \u03b1-D-Arabinonucleosides. Chemistry 2014; 20 (47): 15473\u201315481.","journal-title":"Chemistry"},{"issue":"10","key":"BFijos20163_CR108","doi-asserted-by":"publisher","first-page":"9638","DOI":"10.1021\/acsnano.5b04520","volume":"9","author":"H Zhao","year":"2015","unstructured":"Zhao H, Feng H, Liu D et al. Self-assembling monomeric nucleoside molecular nanoparticles loaded with 5-FU enhancing therapeutic efficacy against oral cancer. ACS Nano 2015; 9 (10): 9638\u20139651.","journal-title":"ACS Nano"}],"container-title":["International Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ijos20163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijos20163","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijos20163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:33:46Z","timestamp":1684431226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijos20163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFijos20163"],"URL":"https:\/\/doi.org\/10.1038\/ijos.2016.3","relation":{},"ISSN":["1674-2818","2049-3169"],"issn-type":[{"value":"1674-2818","type":"print"},{"value":"2049-3169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"5 February 2016","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}